High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy (original) (raw)
Schrader J (2013) The role of MDSCs in hepatocellular carcinoma—in vivo veritas? J Hepatol 59:921–923 ArticlePubMed Google Scholar
Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A et al (2013) The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int 2013:187204. doi:10.1155/2013/187204 ArticlePubMed Google Scholar
Cabrera R, Szabo G (2013) Another armed CD4(+) T cell ready to battle hepatocellular carcinoma. Hepatology 58:1–3 ArticleCASPubMed Google Scholar
Fu J, Zhang Z, Zhou L, Qi Z, Xing S, Lv J et al (2013) Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 58:139–149 ArticleCASPubMed Google Scholar
Pastille E, Bardini K, Fleissner D, Adamczyk A, Frede A, Wadwa M et al (2014) Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. Cancer Res 74:4258–4269 ArticleCASPubMed Google Scholar
Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF (2015) The yin and yang of evasion and immune activation in HCC. J Hepatol 62:1420–1429 ArticleCASPubMed Google Scholar
Huang Y, Wang F, Wang Y, Zhu Z, Gao Y, Ma Z et al (2014) Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma. J Gastroenterol Hepatol 29:851–859 ArticleCASPubMed Google Scholar
Zhang X, Kelaria S, Kerstetter J, Wang J (2015) The functional and prognostic implications of regulatory T cells in colorectal carcinoma. J Gastrointest Oncol 6:307–313 PubMedPubMed Central Google Scholar
Kondo Y, Shimosegawa T (2015) Significant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCs. Int J Mol Sci 16:3307–3322 ArticleCASPubMedPubMed Central Google Scholar
Sharma S, Khosla R, David P, Rastogi A, Vyas A, Singh D et al (2015) CD4+CD25+CD127 (low) regulatory T cells play predominant anti-tumor suppressive role in hepatitis B virus-associated hepatocellular carcinoma. Front Immunol 6:49. doi:10.3389/fimmu.2015.00049 ArticlePubMedPubMed Central Google Scholar
Bailur JK, Gueckel B, Derhovanessian E, Pawelec G (2015) Presence of circulating Her2-reactive CD8+ T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Breast Cancer Res 17:34. doi:10.1186/s13058-015-0541-z ArticlePubMedPubMed Central Google Scholar
Zhang D, Chen Z, Wang DC, Wang X (2015) Regulatory T cells and potential inmmunotherapeutic targets in lung cancer. Cancer Metastasis Rev 34:277–290 ArticleCASPubMed Google Scholar
Yan F, Du R, Wei F, Zhao H, Yu J, Wang C et al (2015) Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients. Cancer Immunol Immunother 64:1475–1485 ArticleCASPubMed Google Scholar
Kurose K, Ohue Y, Sato E, Yamauchi A, Eikawa S, Isobe M et al (2015) Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760). J Thorac Oncol 10:74–83 ArticleCASPubMed Google Scholar
Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM et al (2014) Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63:1769–1781 ArticleCASPubMedPubMed Central Google Scholar
Mao Y, Poschke I, Wennerberg E, de Pico CY, Egyhazi BS, Schultz I et al (2013) Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 73:3877–3887 ArticleCASPubMed Google Scholar
Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H et al (2015) Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 21:30–38 ArticleCASPubMedPubMed Central Google Scholar
Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN et al (2012) IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 1:1460–1468 ArticlePubMedPubMed Central Google Scholar
Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM et al (2014) Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 20:1601–1609 ArticleCASPubMed Google Scholar
Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T et al (2013) Increase in CD14+ HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 62:1421–1430 ArticleCASPubMed Google Scholar
Napolitano M, D’Alterio C, Cardone E, Trotta AM, Pecori B, Rega D et al (2015) Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. Oncotarget 6:8261–8270 ArticlePubMedPubMed Central Google Scholar
Idorn M, Kollgaard T, Kongsted P, Sengelov L, Thor SP (2014) Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 63:1177–1187 ArticleCASPubMed Google Scholar
Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y (2013) Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res 73:2435–2444 ArticleCASPubMedPubMed Central Google Scholar
Medina-Echeverz J, Eggert T, Han M, Greten TF (2015) Hepatic myeloid-derived suppressor cells in cancer. Cancer Immunol Immunother 64:931–940 ArticleCASPubMed Google Scholar
Diaz-Montero CM, Finke J, Montero AJ (2014) Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol 41:174–184 ArticleCASPubMedPubMed Central Google Scholar
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064–5074 ArticleCASPubMedPubMed Central Google Scholar
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020–1030 ArticleCASPubMedPubMed Central Google Scholar
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144 ArticleCASPubMedPubMed Central Google Scholar
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454 ArticleCASPubMedPubMed Central Google Scholar
Andersen MH (2014) The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 28:1784–1792 ArticleCASPubMed Google Scholar
Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S (2013) Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol 191:2829–2836 ArticleCASPubMedPubMed Central Google Scholar
Ostrand-Rosenberg S, Horn LA, Haile ST (2014) The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol 193:3835–3841 ArticleCASPubMedPubMed Central Google Scholar
Woller N, Gurlevik E, Fleischmann-Mundt B, Schumacher A, Knocke S, Kloos AM et al (2015) Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol Ther 23:1630–1640 ArticleCASPubMed Google Scholar
Hato T, Goyal L, Greten TF, Duda DG, Zhu AX (2014) Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology 60:1776–1782 ArticleCASPubMedPubMed Central Google Scholar
Lugade AA, Kalathil S, Miller A, Iyer R, Thanavala Y (2013) High immunosuppressive burden in advanced hepatocellular carcinoma patients: Can effector functions be restored? Oncoimmunology 2:e24679. doi:10.4161/onci.24679 ArticlePubMedPubMed Central Google Scholar
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T et al (2014) Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2:632–642 ArticleCASPubMedPubMed Central Google Scholar
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373:23–34 ArticlePubMed Google Scholar
Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP et al (2004) Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332–4341 ArticleCASPubMed Google Scholar
Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R et al (2014) Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology 59:1415–1426 ArticleCASPubMedPubMed Central Google Scholar
Zhao HQ, Li WM, Lu ZQ, Yao YM (2014) Roles of Tregs in development of hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 20:7971–7978 ArticlePubMedPubMed Central Google Scholar
Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A et al (2015) Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother 64:1271–1286 ArticleCASPubMedPubMed Central Google Scholar
Lee IC, Huang YH, Chau GY, Huo TI, Su CW, Wu JC et al (2013) Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. Int J Cancer 133:2895–2902 ArticleCASPubMed Google Scholar